Related Experiment Video

Updated: Sep 3, 2025

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

15.8K

COVID-19-induced latent relapsing hypercoagulable state in the absence of persistent viral infection

Adrija Hajra1, Juan Torrado1, Carlos L Alviar2

  • 1Department of Internal Medicine, New York City Health and Hospitals-Jacobi Medical Center, New York, NY, USA.

SAGE Open Medical Case Reports
|July 28, 2022
PubMed

Insights

Coronavirus disease 2019 can cause recurring blood clots even without persistent infection. Rebound inflammation, not viral recurrence, may trigger these serious hypercoagulable events.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Hematology

Background:

  • Hypercoagulability is a known complication of coronavirus disease 2019 (COVID-19).
  • Recurrent thrombus formation in COVID-19 patients can be refractory to standard treatments.

Observation:

  • A unique case of chronic COVID-19-induced recurrent thrombi is presented.
  • The patient experienced repeated right ventricular thrombus episodes despite anticoagulation and anti-inflammatory therapy.
  • No evidence of chronic persistent viral infection was found.

Findings:

  • COVID-19 can induce a severe, relapsing hypercoagulable state.
  • Recurrent inflammatory flares, rather than viral persistence, appear to trigger thrombus formation.
  • Standard antithrombotic regimens were ineffective in preventing recurrent clots.

Implications:

  • This case highlights the potential for prolonged hypercoagulability post-COVID-19.
  • Understanding the role of inflammatory flares is crucial for managing recurrent thrombosis.
  • Further research into managing COVID-19-associated hypercoagulability is warranted.

Keywords:
COVID-19anticoagulationpulmonary embolismright ventricular thrombusthrombosis

More Related Videos

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

5.9K
Measurement of γHV68 Infection in Mice13:22

Measurement of γHV68 Infection in Mice

Published on: November 22, 2011

13.7K

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
30
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
37
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
322
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
49
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
488